Ilya Rachman
Net worth: 9 M $ as of 31/07/2026
Net worth: 9 M $ as of 31/07/2026
Ilya Rachman is the founder of Immix Biopharma, Inc., founded in 2012, holding the title of Chairman & Chief Executive Officer.
Dr. Rachman currently holds the positions of Chief Executive Officer, Secretary, and Director at Nexcella, Inc. Education history includes an MBA from the University of California, Los Angeles; graduate and doctorate degrees from the University of Illinois; and an undergraduate degree from the University of Iowa.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 22/05/2026 | 11,41,683 ( 1.6% ) | 9 M $ | 31/07/2026 |
| Companies | Position | Start |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Chief Executive Officer | 01/01/2012 |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immix Biopharma, Inc.
Immix Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cancer patients | Health Technology |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions